A recent study conducted by a Saskatoon-based infectious disease laboratory is delving into the immune responses of humans versus rodents, with the aim of developing effective treatments for hantavirus. This research gains urgency in light of a confirmed outbreak on a cruise ship, which has raised alarms as three fatalities have been reported. The World Health Organization (WHO) is currently monitoring potential exposures among passengers who boarded the ship in Argentina on April 11.
Understanding Hantavirus and Its Carriers
Dr. Bryce Warner, a scientist affiliated with the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan, has indicated that deer mice are the principal carriers of hantavirus. However, other rodent species can also harbour the virus. According to Warner, these deer mice show no signs of illness when infected, allowing them to carry the virus throughout their lives without apparent harm. This contrasts sharply with the severe consequences seen in humans upon infection.
“Hantavirus does not affect deer mice in the same way it does humans,” Warner explained. He noted that while deer mice remain asymptomatic, human infections can lead to serious health complications, including symptoms such as fatigue, dizziness, fever, and, in advanced cases, respiratory distress.
The Current Situation and Health Statistics
Health Canada outlines that hantavirus can present symptoms similar to those of the flu, with progression leading to more serious issues like shortness of breath. While the incidence of hantavirus in Canada is relatively low, averaging five to ten reported cases annually, the stakes are high—around 40 per cent of these cases result in death. Most occurrences are concentrated in Saskatchewan and Alberta, where health authorities are vigilant about monitoring and controlling the spread of the virus.
Dr. Warner emphasises that while the risk of contracting hantavirus remains low, the absence of effective treatment options significantly heightens the potential for fatal outcomes.
Research Goals and Future Directions
The ongoing research at VIDO aims to uncover the distinctions in immune responses between deer mice and humans, with the intention of identifying potential biomarkers for treatment. “We’re in the very early stages of that project,” Warner remarked, underscoring the exploratory nature of their current work.
At present, there are no vaccines approved for hantavirus in Canada or the wider Americas. Although some vaccines have been trialed in the past, little progress has been achieved. Warner mentioned that his laboratory is engaged in early clinical and pre-clinical studies, hoping to develop a viable treatment option. He also noted that while vaccines exist in China and South Korea, they target strains of the virus not prevalent in North America.
Preventative Measures and Public Awareness
As researchers strive to innovate in treatment, Warner stresses the importance of public awareness and preventive measures. The hantavirus can be shed in rodent urine, droppings, and saliva, and can become airborne during cleaning activities in infested areas.
“Awareness is key,” Warner advised. He recommends that individuals take precautions, such as ventilating spaces and employing disinfectants, while also using masks and gloves during clean-up efforts in areas known to have rodent infestations.
Why it Matters
The implications of this research extend far beyond the immediate health concerns associated with hantavirus. As the global community grapples with emerging infectious diseases, understanding and mitigating the risks posed by zoonotic diseases like hantavirus becomes increasingly critical. This study not only seeks to pave the way for effective treatments but also underscores the necessity of public health initiatives aimed at education and prevention, ultimately contributing to a safer environment for all.